. Author manuscript; available in PMC: 2021 Jul 16.

Published in final edited form as: Clin Breast Cancer. 2019 Dec 5;20(3):220–227. doi: 10.1016/j.clbc.2019.11.010

Table 5:

Complementarity of GP88 and CA15–3 Performance in identifying disease progression or response.

Dependent	Biomarker	P value
Progression	GP88	0.0442
Progression	CA15-3	<0.0001

Response	GP88	0.0087
Response	CA15-3	0.6757

Using logistic regression techniques, progression or response was modeled as dependent on the log-transformed GP88 and CA15–3 values. This enabled us to examine the additional information provided by one biomarker to the other in the association with disease progression or response using RECIST 1.1. The logistic regression shows significance for both GP88 (p=0.0442) and CA15–3 (p=0.0001) for association with progression. This means that each biomarker provides statistically significant additive information on progression. When examined for association with response, only GP88 (p=0.0087) showed high statistical significance. This means that GP88 alone is sufficient for monitoring treatment response and CA15–3 (p=0.6757) does not add any value.